Literature DB >> 6488156

Synthesis of S-adenosylethionine by the gamma isozyme of methionine adenosyltransferase from Friend erythroleukemic cells.

R Cox, S Goorha.   

Abstract

Methionine adenosyltransferase (adenosine 5'-triphosphate-L-methionine S-adenosyltransferase, EC 2.5.1.6) was found to occur only as the gamma isozyme in Friend erythroleukemic cells. Enzyme activity in a dialyzed 105,000 X g supernatant was linear for at least 30 min and dependent on the amount of protein added. The Km for methionine was 10.6 microM. In the presence of 10% dimethyl sulfoxide, the enzyme activity was slightly inhibited and dithiothreitol was not required for maximum activity. These properties identify the methionine adenosyltransferase in Friend erythroleukemic cells as the gamma isozyme. L-Ethionine served as a substrate with a Km of 30 microM, and competitively inhibited the enzyme activity with a Ki of 150 microM. Friend erythroleukemic cells grown in the presence of ethionine accumulated S-adenosylethionine, which was dose and time dependent. Therefore, the gamma isozyme of methionine adenosyltransferase from Friend erythroleukemic cells utilize L-ethionine as substrate, resulting in an accumulation of S-adenosylethionine. These studies provide a mechanism by which ethionine through S-adenosylethionine may alter the methylation of DNA in Friend erythroleukemic cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488156

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Modulation of cytosine arabinoside-induced proliferation inhibition by exogenous adenosylmethionine.

Authors:  E Rakasz; J Sugar; O Csuka
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation.

Authors:  Daniel Röth; Abby J Chiang; Weidong Hu; Gabriel B Gugiu; Christina N Morra; James Versalovic; Markus Kalkum
Journal:  FASEB J       Date:  2018-11-19       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.